Nextage Therapeutics Ltd (NXTG) — Cash Flow-to-Debt Ratio
Nextage Therapeutics Ltd (NXTG) has a Cash Flow-to-Debt Ratio of -0.97x as of June 2022, meaning its operating cash flow of ILA-1.72 Million could theoretically repay -1% of its total liabilities (ILA1.77 Million) in one year. See how liquid is Nextage Therapeutics Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Nextage Therapeutics Ltd Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for Nextage Therapeutics Ltd across 8 annual periods. Also explore Nextage Therapeutics Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Nextage Therapeutics Ltd (2017–2024)
Year-by-year debt coverage analysis for Nextage Therapeutics Ltd. For market capitalisation and broader financial context, see Nextage Therapeutics Ltd (NXTG) total market value.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.13x | ILA-795.00K | ILA5.89 Million | ▲ +77.1% |
| 2023 | -0.59x | ILA-2.26 Million | ILA3.83 Million | ▲ +81.0% |
| 2022 | -3.10x | ILA-6.01 Million | ILA1.94 Million | ▼ -193.2% |
| 2021 | -1.06x | ILA-3.97 Million | ILA3.76 Million | ▲ +56.1% |
| 2020 | -2.41x | ILA-6.31 Million | ILA2.62 Million | ▼ -93.1% |
| 2019 | -1.25x | ILA-2.93 Million | ILA2.35 Million | ▼ -79.5% |
| 2018 | -0.70x | ILA-4.95 Million | ILA7.12 Million | ▲ +2.5% |
| 2017 | -0.71x | ILA-5.67 Million | ILA7.96 Million | — |